サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：虚血性視神経症治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤クラス別、投与経路別、疾患タイプ別、流通チャネル別、地域別
市場調査レポート
商品コード
1397310

虚血性視神経症治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤クラス別、投与経路別、疾患タイプ別、流通チャネル別、地域別

Ischemic Optic Neuropathy Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

出版日
ページ情報
英文 223 Pages
納期
2～5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
虚血性視神経症治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤クラス別、投与経路別、疾患タイプ別、流通チャネル別、地域別
出版日: 2023年12月11日
発行: Fairfield Market Research
ページ情報: 英文 223 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の虚血性視神経症治療の市場規模は緩やかに拡大する傾向にあり、2024年の市場収益は2億60万米ドルと推計され、年間平均成長率（CAGR）は5%と予測されており、2031年末には2億8,610万米ドルに達する見込みです。虚血性視神経症治療市場の成長を後押ししている主な要因はいくつかあります。

高齢化人口の増加と、症状のさらなる悪化を防ぐための早期発見の重要性に対する意識の高まりが、視神経障害を治療するための外科手術や薬物療法への関心を高め、市場成長の加速につながっています。

視神経障害の有病率は、これらの疾患の治療に対する需要を押し上げ、市場の成長に寄与しています。世界保健機関（WHO）によると、世界中で13億人以上が視力障害に苦しんでいます。さらに、検眼業界では非侵襲的な医療処置への嗜好が高まっており、市場参入企業にとって魅力的な機会を生み出しています。

虚血性視神経症治療市場は、眼科疾患の管理における以前に承認された眼用インプラントの使用の増加により、さらなる成長が見込まれています。先進国の大手製薬企業や医薬品製造企業は、成長する眼科疾患治療市場でシェアを獲得するため、研究開発、インフラ、先進眼科治療薬に多額の投資を行っており、世界市場の成長をさらに加速させています。

当レポートでは、世界の虚血性視神経症治療市場について調査し、市場の概要とともに、薬剤クラス別、投与経路別、疾患タイプ別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の虚血性視神経症治療市場の見通し、2018年～2031年

  • 世界の虚血性視神経症治療市場の見通し、薬剤クラス別、金額（100万米ドル）、2018年～2031年
  • 世界の虚血性視神経症治療市場の見通し、投与経路別、金額（100万米ドル）、2018年～2031年
  • 世界の虚血性視神経症治療市場の見通し、疾患タイプ別、金額（100万米ドル）、2018年～2031年
  • 世界の虚血性視神経症治療市場の見通し、流通チャネル別、金額（100万米ドル）、2018年～2031年
  • 世界の虚血性視神経症治療市場の見通し、地域別、金額（100万米ドル）、2018年～2031年

第4章 北米の虚血性視神経症治療市場の見通し、2018年～2031年

第5章 欧州の虚血性視神経症治療市場の見通し、2018年～2031年

第6章 アジア太平洋の虚血性視神経症治療市場の見通し、2018年～2031年

第7章 ラテンアメリカの虚血性視神経症治療市場の見通し、2018年～2031年

第8章 中東・アフリカの虚血性視神経症治療市場の見通し、2018年～2031年

第9章 競合情勢

  • 薬物クラスと投与経路のヒートマップ
  • メーカーと投与経路のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競争力ダッシュボード
  • 企業プロファイル
    • Oracle Corporation
    • Merge Healthcare Incorporated
    • Medidata Solutions Inc.
    • PAREXEL International Corporation
    • BioClinica
    • MedNet Solutions, Inc.
    • Bio-Optronics, Inc.
    • DSG, Inc.
    • eClinForce, Inc.
    • Forte Research Systems, Inc.

第10章 付録

目次

The worldwide market for Ischemic Optic Neuropathy Treatment is poised for gradual expansion, with the market revenue estimated at US$ 200.6 Mn in 2024, and a projected Compound Annual Growth Rate (CAGR) of 5% expected to reach a valuation of US$ 286.1 Mn by the end of 2031. Several key factors are driving the growth of the market for the treatment of Ischemic Optic Neuropathy.

Growing Aging Population and Awareness Fuel Demand for Treatment

The increasing aging population and a rising awareness of the importance of early detection to prevent further deterioration of the condition have driven interest in surgical procedures and medications for treating optic nerve disorders, leading to accelerated market growth.

Prevalence of Optic Nerve Disorders Spurs Market Demand

The prevalence of optic nerve disorders is boosting the demand for treatments for these conditions, contributing to market growth. According to the World Health Organization (WHO), over 1.3 billion individuals worldwide suffer from eyesight disorders. Additionally, the growing preference for non-invasive medical procedures in the optometric industry is creating attractive opportunities for market players.

R&D Investments Drive Market Expansion

The Ischemic Optic Neuropathy Treatment market is expected to grow further due to increased use of previously approved ocular implants in managing ophthalmology disorders. Leading pharmaceutical and drug manufacturing companies from developed countries are heavily investing in research and development, infrastructure, and advanced ophthalmology therapeutics to capture a share of the growing eye disorder treatment market, further accelerating global market growth.

Factors Driving Market Growth:

  • 1. Increasing Adoption of Foreign Direct Investment: The rise in foreign direct investment between European countries, Japan, China, and the ASEAN nations has attracted foreign players to explore markets in India and China, expanding their product reach. Domestic players are also exploring new product development strategies in response to these opportunities.
  • 2. Increasing Pool of Diabetic Patients: Ischemic optic neuropathy is commonly associated with diabetes. The increasing prevalence of risk factors such as hypercholesterolemia, diabetes, and hypertension is driving the incidence of this condition.
  • 3. Rising Prevalence of Risk Factors: Several risk factors, including reduced blood flow to the optic nerve, increased intraocular pressure, constricted arteries, and others, contribute to ischemic optic neuropathy. These risk factors are associated with various medical conditions, increasing the likelihood of disease development.

Impact on Global Ischemic Optic Neuropathy Treatment Market:

"Severe Side Effects Associated with High-Dose Corticosteroids Medication": High-dose corticosteroids, commonly used as a first-line treatment for ischemic optic neuropathy, can have severe side effects, including heart attack, kidney failure, lung damage, and more. These side effects can adversely affect patients' health and impede market growth.

"High Medication Costs in Underdeveloped Economies": Licensed medications for the treatment of ischemic optic neuropathy can be expensive, making them unaffordable for patients in underdeveloped economies.

Why is the U.S. Ischemic Optic Neuropathy Treatment Market Booming?

"Better Reimbursement Policies": The United States boasts a well-established healthcare infrastructure and facilities, and it currently holds the largest market share globally. Favorable reimbursement policies and high incomes contribute to the growth of the market in the country.

Will Germany Be a Lucrative Market for Manufacturers?

"Highest Number of Older People in the Region and Robust Healthcare System": Germany's sophisticated and organized healthcare system, along with its focus on research and development in the treatment of eye-related disorders, makes it an attractive market for companies worldwide.

Competitive Landscape:

Manufacturers are keen on diversifying their product portfolios by introducing innovative products and securing approvals from various governmental agencies.

Key Companies' Profiled:

  • AbbVie Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Pfizer Inc.
  • Teva Pharmaceuticals
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche AG
  • Bayer AG
  • Sanofi A.S.
  • Bristol-Myers Squibb and Company

Market Segmentation

Drug Class:

  • Corticosteroids
  • Antimetabolites
  • Anticoagulants
  • Serotonin and norepinephrine reuptake inhibitors (SNRIs)
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Route of Administration:

  • Oral
  • Injectable

Disease Type:

  • Posterior ischemic optic neuropathy
  • Anterior ischemic optic neuropathy

Arteritic AION (A-AION)

Non-Arteritic AION (NA-AION)

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Ischemic Optic Neuropathy Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Ischemic Optic Neuropathy Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
      • 3.1.1.2. Web based Ischemic Optic Neuropathy Treatment
      • 3.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
  • 3.2. Global Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Pharmaceuticals
      • 3.2.1.2. Clinical Research Organizations (CROs)
      • 3.2.1.3. Healthcare Providers
  • 3.3. Global Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
      • 3.3.1.2. Site based Ischemic Optic Neuropathy Treatment
  • 3.4. Global Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospital Pharmacies
      • 3.4.1.2. Retail Pharmacies
      • 3.4.1.3. Drug Stores
      • 3.4.1.4. Online Pharmacies
  • 3.5. Global Ischemic Optic Neuropathy Treatment Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

    • 4.1.1. Key Highlights
      • 4.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
      • 4.1.1.2. Web based Ischemic Optic Neuropathy Treatment
      • 4.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
  • 4.2. North America Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Pharmaceuticals
      • 4.2.1.2. Clinical Research Organizations (CROs)
      • 4.2.1.3. Healthcare Providers
  • 4.3. North America Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
      • 4.3.1.2. Site based Ischemic Optic Neuropathy Treatment
  • 4.4. North America Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies
      • 4.4.1.2. Retail Pharmacies
      • 4.4.1.3. Drug Stores
      • 4.4.1.4. Online Pharmacies
  • 4.5. North America Ischemic Optic Neuropathy Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 4.5.1.2. U.S. Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 4.5.1.3. U.S. Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 4.5.1.4. U.S. Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 4.5.1.5. Canada Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 4.5.1.6. Canada Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 4.5.1.7. Canada Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 4.5.1.8. Canada Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Ischemic Optic Neuropathy Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
      • 5.1.1.2. Web based Ischemic Optic Neuropathy Treatment
      • 5.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
  • 5.2. Europe Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Pharmaceuticals
      • 5.2.1.2. Clinical Research Organizations (CROs)
      • 5.2.1.3. Healthcare Providers
  • 5.3. Europe Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
      • 5.3.1.2. Site based Ischemic Optic Neuropathy Treatment
  • 5.4. Europe Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Retail Pharmacies
      • 5.4.1.3. Drug Stores
      • 5.4.1.4. Online Pharmacies
  • 5.5. Europe Ischemic Optic Neuropathy Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.2. Germany Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.3. Germany Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.4. Germany Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.5. U.K. Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.6. U.K. Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.7. U.K. Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.8. U.K. Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.9. France Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.10. France Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.11. France Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.12. France Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.13. Italy Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.14. Italy Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.15. Italy Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.16. Italy Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.17. Turkey Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.18. Turkey Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.19. Turkey Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.20. Turkey Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.21. Russia Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.22. Russia Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.23. Russia Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.24. Russia Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
      • 6.1.1.2. Web based Ischemic Optic Neuropathy Treatment
      • 6.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
  • 6.2. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Pharmaceuticals
      • 6.2.1.2. Clinical Research Organizations (CROs)
      • 6.2.1.3. Healthcare Providers
  • 6.3. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
      • 6.3.1.2. Site based Ischemic Optic Neuropathy Treatment
  • 6.4. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Retail Pharmacies
      • 6.4.1.3. Drug Stores
      • 6.4.1.4. Online Pharmacies
  • 6.5. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.2. China Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.3. China Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.4. China Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.5. Japan Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.6. Japan Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.7. Japan Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.8. Japan Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.9. South Korea Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.10. South Korea Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.11. South Korea Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.12. South Korea Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.13. India Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.14. India Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.15. India Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.16. India Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
      • 7.1.1.2. Web based Ischemic Optic Neuropathy Treatment
      • 7.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
  • 7.2. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Pharmaceuticals
      • 7.2.1.2. Clinical Research Organizations (CROs)
      • 7.2.1.3. Healthcare Providers
  • 7.3. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
      • 7.3.1.2. Site based Ischemic Optic Neuropathy Treatment
  • 7.4. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Retail Pharmacies
      • 7.4.1.3. Drug Stores
      • 7.4.1.4. Online Pharmacies
  • 7.5. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Hardware
      • 7.5.1.2. Services
  • 7.6. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.6.1. Key Highlights
      • 7.6.1.1. Brazil Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.6.1.2. Brazil Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.6.1.3. Brazil Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 7.6.1.4. Brazil Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.6.1.5. Mexico Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.6.1.6. Mexico Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.6.1.7. Mexico Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 7.6.1.8. Mexico Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.6.1.9. Argentina Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.6.1.10. Argentina Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.6.1.11. Argentina Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 7.6.1.12. Argentina Ischemic Optic Neuropathy Treatment Market by Distribution Type, Value (US$ Mn), 2018 - 2031
      • 7.6.1.13. Rest of Latin America Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.6.1.14. Rest of Latin America Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.6.1.15. Rest of Latin America Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 7.6.1.16. Rest of Latin America Ischemic Optic Neuropathy Treatment Market by Distribution Type, Value (US$ Mn), 2018 - 2031
    • 7.6.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
      • 8.1.1.2. Web based Ischemic Optic Neuropathy Treatment
      • 8.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
  • 8.2. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Pharmaceuticals
      • 8.2.1.2. Clinical Research Organizations (CROs)
      • 8.2.1.3. Healthcare Providers
  • 8.3. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
      • 8.3.1.2. Site based Ischemic Optic Neuropathy Treatment
  • 8.4. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Retail Pharmacies
      • 8.4.1.3. Drug Stores
      • 8.4.1.4. Online Pharmacies
  • 8.5. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.2. GCC Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.3. GCC Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.4. GCC Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.5. South Africa Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.6. South Africa Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.7. South Africa Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.8. South Africa Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.9. Egypt Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.10. Egypt Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.11. Egypt Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.12. Egypt Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.13. Nigeria Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.14. Nigeria Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.15. Nigeria Ischemic Optic Neuropathy Treatment Market Disease Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.16. Nigeria Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Drug Class vs Route of Administration Heatmap
  • 9.2. Manufacturer vs Route of Administration Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Oracle Corporation
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Drug Class Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Merge Healthcare Incorporated
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Drug Class Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Medidata Solutions Inc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Drug Class Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. PAREXEL International Corporation
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Drug Class Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. BioClinica
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Drug Class Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. MedNet Solutions, Inc.
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Drug Class Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Bio-Optronics, Inc.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Drug Class Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. DSG, Inc.
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Drug Class Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. eClinForce, Inc.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Drug Class Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Forte Research Systems, Inc.
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Drug Class Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations